Brepocitinib tosylate

Brepocitinib Tosylate is the tosylate form of brepocitinib, an orally available, selective inhibitor of non-receptor tyrosine-protein kinase TYK2 (tyrosine kinase 2) and tyrosine-protein kinase JAK1 (Janus kinase 1; JAK1), with potential immunomodulatory and anti-inflammatory activities. It is grouped under the following drug class(es): Tyrosine Kinase Inhibitors. The directory classifies it as a clinical API with a synthetic source/manufacturing origin. Other names for this substance include Methanone, ((1S)-2, 2-difluorocyclopropyl)(3-(2-((1-methyl-1H-pyrazol-4-yl)amino)-4-pyrimidinyl)-3, 8-diazabicyclo(3.2.1)oct-8-yl)- and 4-methylbenzenesulfonate (1:1). Its PubChem CID is 124203834.

CAS No 2140301-96-6
Molecular Formula C25H29F2N7O4S
Molecular Weight 561.6 g/mol
Synonyms [(1S)-2,2-difluorocyclopropyl]-[(1S,5R)-3-[2-[(1-methylpyrazol-4-yl)amino]pyrimidin-4-yl]-3,8-diazabicyclo[3.2.1]octan-8-yl]methanone;4-methylbenzenesulfonic acid

Frequently Asked Questions